Literature DB >> 12512304

Gene therapy of X-linked severe combined immunodeficiency.

Salima Hacein-Bey-Abina1, Genevieve de Saint Basile, Marina Cavazzana-Calvo.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12512304     DOI: 10.1385/1-59259-345-3:247

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


× No keyword cloud information.
  5 in total

1.  Evaluation of residual promoter activity in γ-retroviral self-inactivating (SIN) vectors.

Authors:  Wenqin Xu; Jill L Russ; Maribeth V Eiden
Journal:  Mol Ther       Date:  2011-10-18       Impact factor: 11.454

2.  Intasome architecture and chromatin density modulate retroviral integration into nucleosome.

Authors:  Mohamed Salah Benleulmi; Julien Matysiak; Daniel Rodrigo Henriquez; Cédric Vaillant; Paul Lesbats; Christina Calmels; Monica Naughtin; Oscar Leon; Anna Marie Skalka; Marc Ruff; Marc Lavigne; Marie-Line Andreola; Vincent Parissi
Journal:  Retrovirology       Date:  2015-02-07       Impact factor: 4.602

3.  Advances in Non-Viral DNA Vectors for Gene Therapy.

Authors:  Cinnamon L Hardee; Lirio Milenka Arévalo-Soliz; Benjamin D Hornstein; Lynn Zechiedrich
Journal:  Genes (Basel)       Date:  2017-02-10       Impact factor: 4.096

4.  Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency.

Authors:  Susannah I Thornhill; Axel Schambach; Steven J Howe; Meera Ulaganathan; Elke Grassman; David Williams; Bernhard Schiedlmeier; Neil J Sebire; H Bobby Gaspar; Christine Kinnon; Christopher Baum; Adrian J Thrasher
Journal:  Mol Ther       Date:  2008-01-08       Impact factor: 11.454

Review 5.  Genetically modified mesenchymal stromal cells in cancer therapy.

Authors:  Elizabeth K Sage; Ricky M Thakrar; Sam M Janes
Journal:  Cytotherapy       Date:  2016-11       Impact factor: 5.414

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.